1. Rangasami JJ, Greenwood DC, McSporran B,
Smail PJ, Patterson CC, Waugh NR. Rising
incidence of type 1 diabetes in Scottish children,
1984–93. The Scottish Study Group for the Care
of Young Diabetics. Arch Dis Child 1997;77:210–13.
2. Bingley PJ, Gale EA. Incidence of insulin
dependent diabetes in England: a study in the
Oxford region, 1985–6. BMJ 1989;298:558–60.
3. Zhao HX, Stenhouse E, Soper C, Hughes P,
Sanderson E, Baumer JH, et al. Incidence of
childhood-onset type 1 diabetes mellitus in Devon
and Cornwall, England, 1975–1996. Diabet Med
1999;16:1030–5.
4. Burden AC, Hearnshaw JR, Swift PG. Childhood
diabetes mellitus: an increasing incidence. Diabet
Med 1989;6:334–6.
5. Patterson CC, Thorogood M, Smith PG,
Heasman MA, Clarke JA, Mann JI. Epidemiology
of type 1 (insulin-dependent) diabetes in Scotland
1968–1976: evidence of an increasing incidence.
Diabetologia 1983;24:238–43.
6. Patterson CC, Smith PG, Webb J, Heasman MA,
Mann JI. Geographical variation in the incidence
of diabetes mellitus in Scottish children during the
period 1977–1983. Diabet Med 1988;5:160–5.
7. Staines A, Bodansky HJ, Lilley HE, Stephenson C,
McNally RJ, Cartwright RA. The epidemiology of
diabetes mellitus in the United Kingdom: the
Yorkshire Regional Childhood Diabetes Register.
Diabetologia 1993;36:1282–7.
8. Green A, Gale EA, Patterson CC. Incidence of
childhood-onset insulin-dependent diabetes
mellitus: the EURODIAB ACE Study. Lancet
1992;339:905–9.
9. UKPDS Study Group. Intensive blood glucose
control with sulphonylureas or insulin compared
with conventional treatment and risk of
complications in patients with type 2 diabetes
(UKPDS 33). Lancet 1998;352:837–53.
10. Neil HA, Gatling W, Mather HM. The Oxford
Community Diabetes Study: evidence for an
increase in the prevalence of known diabetes in
Great Britain. Diabet Med 1987;4:539–43.
11. Gatling W, Budd S, Walters D, Mulle MA,
Goddard JR, Hill RD. Evidence of an increasing
prevalence of diagnosed diabetes in the Poole area
from 1983 to 1996. Diabet Med 1998;15:1015–21.
12. Mather HM, Keen H. The Southall Diabetes
Survey: prevalence of known diabetes in Asians
and Europeans. BMJ 1985;291:1081–4.
13. Newnham A, Ryan R, Khunti K, Majeed A.
Prevalence of diagnosed diabetes mellitus in
general practice in England and Wales, 1940 to
1998. Health Stat Q 2002;14:5–13.
14. Turner R, Cull C, Holman R, for the United
Kingdom Prospective Diabetes Study. UKPDS 17:
A 9-year update of a randomised controlled trial
of the effect of improved metabolic control on
complications in non-insulin-dependant diabetes
mellitus. Ann Intern Med 1996;124:136–45.
15. Waugh NR, Jung RT, Newton RW. The Dundee
prevalence study of insulin-treated diabetes;
intervals between diagnosis and start of insulin
therapy. Diabet Med 1989;6:346–50.
16. Humphrey ARG, McCarty DJ, Mackay IR,
Rowley MJ, Dwyer T, Zimmet P. Autoantibodies to
glutamic acid decarboxylase and phentotypic
features associated with early insulin treatment in
individuals with adult-onset diabetes. Diabet Med
1998;15:113–19.
17. Office for National Statistics. Key health statistics
from general practice 1998. London: Office for
National Statistics; 2000.
18. Wang PH, Lau J, Chalmers TC. Meta-analysis of
effects of intensive blood-glucose control on late
complications of type I diabetes. Lancet
1993;341:1306–9.
19. The Diabetes Control and Complications Trial
Research Group. The effect of intensive treatment
of diabetes on the development and progression of
long-term complications in insulin-dependent
diabetes mellitus. N Engl J Med 1993;329:977–86.
20. Reichard P, Nilsson B-Y, Rosenqvist U. The effect
of long-term intensified insulin treatment on the
development of microvascular complications of
diabetes mellitus. N Engl J Med 1993;329:304–9.
21. The Diabetes Control and Complications Trial.
The effect of intensive diabetes treatment on the
progression of diabetic retinopathy in insulindependent
diabetes mellitus. Arch Ophthalmol
1995;113:36–51.
22. Egger M, Davey-Smith G, Stettler C, Diem P.
Risk of adverse effects of intensified treatment in
insulin-dependent diabetes mellitus: a metaanalysis.
Diabet Med 1997;14:919–28.
23. Gold AE, Frier BM. Hypoglycaemia: practical and
clinical implications. In Kelnar CJH, editor.
Childhood and adolescent diabetes, London: Chapman
and Hall; 1995. pp. 351–66.
24. The Diabetes Control and Complications Trial
Research Group. Hypoglycemia in the Diabetes
Control and Complications Trial. Diabetes
1997;46:271–86.
25. Muhlhauser I, Berger M, Sonnenberg G, Koch J,
Jorgens V, Schernthaner G, et al. Incidence and
management of severe hypoglycemia in 434 adults
with insulin-dependent diabetes mellitus. Diabetes
Care 1985;8:268–73.
26. Rewers A, Chase HP, Mackenzie T, Walravens P,
Roback M, Rewers M, et al. Predictors of acute
complications in children with type 1 diabetes.
JAMA 2002;287:2511–18.
27. Emilien G, Maloteaux JM, Ponchon M.
Pharmacological management of diabetes: recent
progress and future perspective in daily drug
treatment. Pharmacol Ther 1999;81:37–51.
28. Swift PGF. Insulin: types and regimens. Childhood
and adolescent diabetes. London: Chapman and
Hall; 1995. pp. 253–66.
29. Morris AD, Boyle DIR, McMahon AD, for the
DARTS/MEMO Collaboration. Adherence to
insulin treatment, glycaemic control and
ketoacidosis in IDDM. Lancet 1997;350:1505–10.
30. Scottish Study Group for the Care of the Young
Diabetic. Factors influencing glycemic control in
young people with type 1 diabetes in Scotland. A
population-based study (DIABAUD2). Diabetes Care
2001;24:239–44.
31. Atkinson MA, Eisenbarth GS. Type 1 diabetes:
new perspectives on disease pathogenesis and
treatment. Lancet 2001;358:221–9.
32. Pickup JC, Keen H, Parsons JA, Alberti KGMM.
Continuous subcutaneous insulin infusion: an
approach to achieving normoglycaemia. BMJ
1978;i:204–7.
33. Tamborlane WV, Sherwin RS, Genel M, Felig P.
Reduction to normal of plasma glucose in juvenile
diabetes by subcutaneous administration of insulin
with a portable infusion pump. N Engl J Med
1979;300:573–8.
34. Thorp FK. Insulin pump therapy reconsidered.
JAMA 1986;255:645–6.
35. Davies AG, Baum JD. A decade of insulin infusion
pumps. Arch Dis Child 1988;63:329–32.
36. Lenhard MJ, Reeves GD. Continuous
subcutaneous insulin infusion: a comprehensive
review of insulin pump therapy. Arch Intern Med
2001;161:2293–300.
37. American Diabetes Association. Continuous
subcutaneous insulin infusion. Diabetes Care
2002;25:S116.
38. Pickup J, Keen H. Continuous subcutaneous
insulin infusion in type 1 diabetes is beneficial in
selected patients and should be more widely
available. BMJ 2001;322:1263–4.
39. Pickup J, Keen H. Continuous subcutaneous
insulin infusion at 25 years: Evidence base for the
expanding use of insulin pump therapy in type 1
diabetes. Diabetes Care 2002;25:593–8.
40. Pickup J, Mattock M, Kerry S. Glycaemic control
with continuous subcutaneous insulin infusion
compared with intensive insulin injections in
patients with type 1 diabetes: meta-analysis of
randomised controlled trials. BMJ 2002;324:705–8.
41. Pons JMV. Continuous subcutaneous infusion of insulin
with portable pump in diabetes type 1 patients.
Barcelona: CAHTA; 2000. No. IN01/2000.
42. Munoz A, Saz Z, Amate JM. Efficacy of insulin
infusion pumps. Impact on the quality of live of certain
patients. Spain: AETS; 2000.
43. Hotta SS, Adams D. Reassessment of external
insulin infusion pumps. Health Technol Assess
Reports 1990;(9):1–9.
44. Graff MR, Rubin RR, Walker EA. How diabetes
specialists treat their own diabetes: findings from a
study of the AADE and ADA membership. Diabetes
Educ 2000;26:460–7.
45. Wredling R, Lin PE, Adamson U. Pump ‘run-away’
causing severe hypoglycaemia. Lancet 1989;ii:273.
46. Tritos NA, Casper K, King G. Museum visit
leading to insulin pump malfunction. Ann Intern
Med 1997;126:746.
47. Darmon P, Guillaume V, Wiart J, Dutour A,
Oliver C. Do mobile cellular phones interfere with
portable insulin pumps? Diabetes Care 1998;
21:1775.
48. Prendergast JJ, Dorsey C, Elsea V. Over-delivery of
insulin by insulin pumps. Diabetes Care 1995;
18:1201–2.
49. Mecklenburg RS, Benson EA, Benson JW,
Fredlund PN, Guinn T, Metz RJ, et al. Acute
complications associated with insulin infusion
pump therapy. Report of experience with 161
patients. JAMA 1984;252:3265–9.
50. Teutsch SM, Herman WH, Dwyer DM, Lane JM.
Mortality among diabetic patients using
continuous subcutaneous insulin-infusion pumps.
N Engl J Med 1984;310:361–8.
51. Knight G, Jennings AM, Boulton AJ, Tomlinson S,
Ward JD. Severe hyperkalaemia and ketoacidosis
during routine treatment with an insulin pump.
BMJ 1985;291:371–2.
52. The Kroc Collaborative Study Group. Blood
glucose control and the evolution of diabetic
retinopathy and albuminuria. A preliminary
multicenter trial. N Engl J Med 1984;311:365–72.
53. Steel JM, West CP. Intrauterine death during
continuous subcutaneous infusion of insulin. BMJ
1985;290:1787.
54. Bradley C, Gamsu DS, Knight G, Boulton AJ,
Ward JD. Predicting risk of diabetic ketoacidosis in
patients using continuous subcutaneous insulin
infusion. BMJ 1986;293:242–3.
55. Bending JJ, Pickup JC, Keen H. Frequency of
diabetic ketoacidosis and hypoglycemic coma
during treatment with continuous subcutaneous
insulin infusion. Audit of medical care. Am J Med
1985;79:685–91.
56. Chantelau E, Spraul N, Mhuhlhauser I, Gause R,
Beger M. Long-term safety, efficacy and sideeffects
of continuous subcutaneous insulin infusion
treatment for type 1 (insulin-dependent) diabetes
mellitus: a one centre experience. Diabetologia
1989;32:421–6.
57. Raskin P. Treatment of type 1 diabetes with
portable insulin pumps. Diabetes Care 1982;5
(Suppl 1):48–52.
58. Toth EL, Boychuk LR, Kirkland PA. Recurrent
infection of continuous subcutaneous insulin
infusion sites with Mycobacterium fortuitum. Diabetes
Care 1995;18:1284–5.
59. Pagnoux C, Nassif X, Boitard C, Timsit J.
Infection of continuous subcutaneous insulin
infusion site with Mycobacterium peregrinum. Diabetes
Care 1998;21:191–2.
60. New insulin pump forum launched in UK.
Pract Diab Int 2000;17:278–9.
61. Brink SJ, Stewart C. Insulin pump treatment in
insulin-dependent diabetes mellitus. Children,
adolescents, and young adults. JAMA 1986;
255:617–21.
62. Levy-Marchal C, Czernichow P. Feasibility of
continuous subcutaneous insulin infusion in young
diabetic patients. Diabetes Metab 1988;14:108–13.
63. Knight G, Boulton AJ, Ward JD. Experience of
continuous subcutaneous insulin infusion in the
outpatient management of diabetic teenagers.
Diabet Med 1986;3:82–4.
64. Bougneres PF, Landier F, Lemmel C, Mensire A,
Chaussain JL. Insulin pump therapy in young
children with type 1 diabetes. J Pediatr 1984;
105:212–7.
65. De Beaufort CE, Bruining GJ. Continuous
subcutaneous insulin infusion in children.
Diabet Med 1987;4:103–8.
66. Kaufman FR, Halvorson M, Kim C,
Pitukcheewanont P. Use of insulin pump therapy
at nighttime only for children 7–10 years of age
with type 1 diabetes. Diabetes Care 2000;23:579–82.
67. Schiffrin A. Nighttime continuous subcutaneous
insulin infusion revisited: a strategy for improving
insulin delivery. Diabetes Care 2000;23:571–3.
68. Olsson P, Arnqvist H, Von Schenck H,
Ottosson AM. Overnight metabolic control with
bedtime injection of intermediate-acting insulin or
continuous subcutaneous insulin fusion. Diabetes
Care 1987;10:702–6.
69. Kanc K, Janssen MM, Keulen ET, Jacobs MA,
Popp-Snijders C, Snoek FJ, et al. Substitution of
night-time continuous subcutaneous insulin
infusion therapy for bedtime NPH insulin in a
multiple injection regimen improves
counterregulatory hormonal responses and
warning symptoms of hypoglycaemia in IDDM.
Diabetologia 1998;41:322–9.
70. Gabbe SG. New concepts and applications in the
use of the insulin pump during pregnancy.
J Matern Fetal Med 2000;9:42–5.
71. Aucott SW, Williams TG, Hertz RH, Kalhan SC.
Rigorous management of insulin-dependent
diabetes mellitus during pregnancy. Acta Diabetol
1994;31:126–9.
72. Caruso A, Lanzone A, Bianchi V, Massidda M,
Castelli MP, Fulghesu AM, et al. Continuous
subcutaneous insulin infusion (CSII) in pregnant
diabetic patients. Prenat Diagn 1987;7:41–50.
73. Jensen BM, Kuhl C, Molsted-Pedersen L,
Saurbrey N, Fog-Pedersen J. Preconceptional
treatment with insulin infusion pumps in insulindependent
diabetic women with particular
reference to prevention of congenital
malformations. Acta Endocrinol Suppl (Copenh)
1986;277:81–5.
74. Rudolf MC, Coustan DR, Sherwin RS, Bates SE,
Felig P, Genel M, et al. Efficacy of the insulin pump
in the home treatment of pregnant diabetics.
Diabetes 1981;30:891–5.
75. Simmons D, Thompson CF, Conroy C, Scott DJ.
Use of insulin pumps in pregnancies complicated
by Type 2 diabetes and gestational diabetes in a
multiethnic community. Diabetes Care
2001;24:2078–82.
76. Brinchmann-Hansen O, Dahl-Jorgensen K,
Hanssen KF, Sandvik L. The response of diabetic
retinopathy to 41 months of multiple insulin
injections, insulin pumps, and conventional insulin
therapy. Arch Ophthalmol 1988;106:1242–6.
77. Dahl-Jorgensen K, Hanssen KF, Kierulf P, Bjoro T,
Sandvik L, Aagenaes O. Reduction of urinary
albumin excretion after 4 years of continuous
subcutaneous insulin infusion in insulindependent
diabetes mellitus. The Oslo Study. Acta
Endocrinologica 1988;117:19–25.
78. Dahl-Jorgensen K, Brinchmann-Hansen O,
Hanssen KF, Ganes T, Kierulf P, Smeland E, et al.
Effect of near normoglycaemia for two years on
progression of early diabetic retinopathy,
nephropathy, and neuropathy: the Oslo study. BMJ
1986;293:1195–9.
79. Tsui E, Barnie A, Ross S, Parkes R, Zinman B.
Intensive insulin therapy with insulin lispro: a
randomized trial of continuous subcutaneous
insulin infusion versus multiple daily insulin
injection. Diabetes Care 2001;24:1722–7.
80. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S,
Tauber JP. Comparison of continuous
subcutaneous insulin infusion and multiple daily
injection regimens using insulin lispro in type 1
diabetic patients on intensified treatment: a
randomized study. The Study Group for the
Development of Pump Therapy in Diabetes.
Diabetes Care 2000;23:1232–5.
81. Bode BW, Steed RD, Davidson PC. Reduction in
severe hypoglycemia with long-term continuous
subcutaneous insulin infusion in type I diabetes.
Diabetes Care 1996;19:324–7.
82. Chiasson JL, Ducros F, Poliquin HM, Lopez D,
Lecavalier L, Hamet P. Continuous subcutaneous
insulin infusion (Mill-Hill Infuser) versus multiple
injections (Medi-Jector) in the treatment of
insulin-dependent diabetes mellitus and the effect
of metabolic control on microangiopathy. Diabetes
Care 1984;7:331–7.
83. Haakens K, Hanssen KF, Dahl-Jorgensen K,
Vaaler S, Aagenaes O, Mosand R. Continuous
subcutaneous insulin infusion (CSII), multiple
injections (MI) and conventional insulin therapy
(CT) in self-selecting insulin-dependent diabetic
patients. A comparison of metabolic control, acute
complications and patient preferences. J Intern
Med 1990;228:457–64.
84. Ziegler D, Dannehl K, Koschinsky T, Toeller M,
Gries FA. Comparison of continuous subcutaneous
insulin infusion and intensified conventional
therapy in the treatment of type I diabetes: a twoyear
randomized study. Diabetes Nutr Metab Clin
Exp 1990;3:203–13.
85. Nosadini R, Velussi M, Fioretto P, Doria A,
Avogaro A, Trevisan R, et al. Frequency of
hypoglycaemic and hyperglycaemic–ketotic
episodes during conventional and subcutaneous
continuous insulin infusion therapy in IDDM.
Diabetes Nutr Metab 1988;1:289–96.
86. Schmitz A, Christiansen JS, Christensen CK,
Hermansen K, Mogensen CE. Effect of pump
versus pen treatment on glycaemic control and
kidney function in long-term uncomplicated
insulin-dependent diabetes mellitus (IDDM). Dan
Med Bull 1989;36:176–8.
87. Bak JF, Nielsen OH, Pedersen O, Beck-Nielsen H.
Multiple insulin injections using a pen injector
versus insulin pump treatment in young diabetic
patients. Diabetes Res 1987;6:155–8.
88. Home PD, Capaldo B, Burrin JM, Worth R,
Alberti KG. A crossover comparison of continuous
subcutaneous insulin infusion (CSII) against
multiple insulin injections in insulin-dependent
diabetic subjects: improved control with CSII.
Diabetes Care 1982;5:466–71.
89. Nathan DM, Lou PAJ. Intensive conventional and
insulin pump therapy in adult type 1 diabetes.
A crossover study. Ann Intern Med 1982;97:31–6.
90. Saurbrey N, Arnold-Larsen S, Moller-Jensen B,
Kuhl C. Comparison of continuous subcutaneous
insulin infusion with multiple insulin injections
using the NovoPen. Diabet Med 1988;5:150–3.
91. Schiffrin A, Belmonte MM. Comparison between
continuous subcutaneous insulin infusion and
multiple injection of insulin. A one-year
prospective study. Diabetes 1982;31:255–64.
92. Nosari I, Maglio ML, Lepore G. Is continuous
subcutaneous insulin infusion more effective than
intensive conventional insulin therapy in the
treatment of pregnant diabetic women? Diabetes
Nutr Metab 1993;6:33–7.
93. Coustan DR, Reece EA, Sherwin RS, Rudolf MC,
Bates SE, Sockin SM, et al. A randomized clinical
trial of the insulin pump vs intensive conventional
therapy in diabetic pregnancies. JAMA
1986;255:631–6.
94. Carta Q, Meriggi E, Trossarelli GF, Catella G,
Dal Molin V, Menato G, et al. Continuous
subcutaneous insulin infusion versus intensive
conventional insulin therapy in type I and type II
diabetic pregnancy. Diabetes Metab 1986;12:121–9.
95. Burkart W, Hanker JP, Schneider HP.
Complications and fetal outcome in diabetic
pregnancy. Intensified conventional versus insulin
pump therapy. Gynecol Obstet Invest 1988;
26:104–12.
96. Tamborlane WV, Batas SE, Rudolf MC.
Comparison of continuous subcutaneous insulin
infusion versus multiple daily injections in
adolescents with insulin-dependent diabetes.
Adv Diabetol 1989;2 (Suppl 1):24–7.
97. Schiffrin AD, Desrosiers M, Aleyassine H,
Belmonte MM. Intensified insulin therapy in the
type 1 diabetic adolescent: a controlled trial.
Diabetes Care 1984;7:107–13.
98. Boland EA, Grey M, Oesterle A, Fredrickson L,
Tamborlane WV. Continuous subcutaneous insulin
infusion. A new way to lower risk of severe
hypoglycemia, improve metabolic control, and
enhance coping in adolescents with type 1
diabetes. Diabetes Care 1999;22:1779–84.
99. Mack-Fogg J, Bates S, Faro B, Sciera M,
Ippolito K, Orlowski CC, et al. Safe and effective
use of continuous subcutaneous insulin infusion in
young children with type 1 diabetes mellitus.
Diabetes 2002;51 (Suppl 1, poster 712):122A.
100. Rudolf JW, Hirsch IB. An assessment of
continuous subcutaneous insulin infusion therapy in an academic diabetes clinic. Diabetes 2000;
49 (Suppl 1, poster 501-P):A124.
101. Haardt MJ, Berne C, Dorange C, Slama G,
Selam JL. Efficacy and indications of CSII revisited:
the Hotel-Dieu cohort. Diabet Med 1997;14:407–8.
102. Tamborlane WV, Bonfig W, Boland E. Recent
advances in treatment of youth with type 1
diabetes: better care through technology. Diabet
Med 2001;18:864–70.
103. Kaufman FR, Halvorson M, Miller D,
Mackenzie M, Fisher LK, Pitukcheewanont P.
Insulin pump therapy in type 1 pediatric patients:
now and into the year 2000. Diabetes Metab Res Rev
1999;15:338–52.
104. Plotnick L, Clark L. Insulin pumps in children and
adolescents. Endocrinologist 2001;11:112–17.
105. Steindel BS, Roe TR, Costin G, Carlson M,
Kaufman FR. Continuous subcutaneous insulin
infusion (CSII) in children and adolescents with
chronic poorly controlled type 1 diabetes mellitus.
Diabetes Res Clin Pract 1995;27:199–204.
106. Maniatis AK, Klingensmith GJ, Slover RH,
Mowry CJ, Chase HP. Continuous subcutaneous
insulin infusion therapy for children and
adolescents: an option for routine diabetes care.
Pediatrics 2001;107:351–6.
107. Conrad SC, McGrath MT, Gitelman SE.
Transition from multiple daily injections to
continuous subcutaneous insulin infusion in type 1
diabetes mellitus. J Pediatr 2002;140:235–40.
108. Ahern JA, Boland E, Doane R, Ahern JJ, Rose P,
Vincent M, et al. Insulin pump therapy in
pediatrics: a therapeutic alternative to safely lower
HbA1c levels across all age groups. Pediatr Diabetes
2002;3:10–15.
109. Fox LA, Wilkinson K, Buckloh L, Wysocki T,
Mauras N. A randomized trial of insulin pump
therapy in preschool age children with type 1
diabetes mellitus: preliminary results. Diabetes
2002;51 (Suppl 2, poster 1751):426A.
110. Weintrob N, Benzaquen H, Galatzer A, Shalitin S,
Lazar L, Fayman G, et al. Comparison of
continuous subcutaneous insulin infusion and
multiple daily injection regimens in children with
type 1 diabetes: a randomised controlled trial.
Diabetes 2002;51 (Suppl 2, poster 1969).
111. Valensi P, Moura I, Le Magoarou M, Paries J,
Perret G, Attali JR. Short-term effects of
continuous subcutaneous insulin infusion
treatment on insulin secretion in non-insulindependent
overweight patients with poor
glycaemic control despite maximal oral antidiabetic
treatment. Diabetes Metab 1997;23:51–7.
112. Dupuy O, Mayaudon H, Palou M, Sarret D,
Bordier L, Bauduceau B. Optimized transient
insulin infusion in uncontrolled type 2 diabetes:
evaluation of a pragmatic attitude. Diabetes Metab
2000;26:371–5.
113. Bode B, Weinstein R, Bell D, McGill J, Nadeau D,
Raskin P, et al. Comparison of insulin aspart with
buffered regular insulin and insulin lispro in
continuous subcutaneous insulin infusion: a
randomized study in type 1 diabetes. Diabetes Care
2002;25:439–44.
114. Renner R, Pfutzner A, Trautmann M, Harzer O,
Sauter K, Landgraf R. Use of insulin lispro in
continuous subcutaneous insulin infusion
treatment. Results of a multicenter trial. German
Humalog-CSII Study Group. Diabetes Care 1999;
22:784–8.
115. Schmauss S, Konig A, Landgraf R. Human insulin
analogue [LYS(B28), PRO(B29)]: the ideal pump
insulin? Diabet Med 1998;15:247–9.
116. Melki V, Renard E, Lassmann-Vague V, Boivin S,
Guerci B, Hanaire-Broutin H, et al. Improvement
of HbA1c and blood glucose stability in IDDM
patients treated with lispro insulin analog in
external pumps. Diabetes Care 1998;21:977–82.
117. Raskin P, Holcombe JH, Tamborlane WV, Malone
JI, Strowig S, Ahern JA, et al. A comparison of
insulin lispro and buffered regular human insulin
administered via continuous subcutaneous insulin
infusion pump. J Diabetes Complications 2001;
15:295–300.
118. Zinman B, Tildesley H, Chiasson JL, Tsui E,
Strack T. Insulin lispro in CSII: results of a doubleblind
crossover study. Diabetes 1997;46:440–3.
119. Green S, Deeks J, Savio F. The ends and the
means: continuous data in Cochrane reviews.
Poster presentation at Cochrane Colloquium,
2001.
120. Schifferdecker E, Schmidt K, Boehm BO, Schatz H.
Long-term compliance of intensified insulin
therapy. Diabetes Res Clin Pract 1994;23:17–23.
121. Wredling R, Lins PE, Adamson U. Factors
influencing the clinical outcome of continuous
subcutaneous insulin infusion in routine practice.
Diabetes Res Clin Pract 1993;19:59–67.
122. Knight G, Boulton AJ, Drury J, Gamsu DS,
Moses JL, Bradley C, et al. A feasibility study of
the use of continuous subcutaneous insulin
infusion in a diabetic clinic: patients’ choice of
treatment. Diabet Med 1984;1:267–72.
123. Floyd JC, Cornell RG, Jacober SJ, Griffith LE,
Funnell MM, Wolf LL, et al. A prospective study
identifying risk factors for discontinuance of
insulin pump therapy. Diabetes Care 1993;
16:1470–8.
124. Bell DS, Ackerson C, Cutter G, Clements RS.
Factors associated with discontinuation of
continuous subcutaneous insulin infusion. Am J Med Sci 1988;295:23–8.
125. Bell DSH, Cutter G, Clements J. The feasibility of
long-term treatment of diabetes with continuous
subcutaneous insulin infusion. Diabetes Nutr Metab
Clin Exp 1993;6:57–60.
126. British National Formulary. London: British
National Formulary; 2002.
127. Herman WH, Eastman RC. The effects of
treatment on the direct costs of diabetes. Diabetes
Care 1998;21:C19–24.
128. American Diabetes Association. Economic
consequences of diabetes mellitus in the U.S. in
1997. Diabetes Care 1998;21:296–309.
129. Lifetime benefits and costs of intensive therapy as
practiced in the diabetes control and
complications trial. The Diabetes Control and
Complications Trial Research Group. JAMA
1996;276:1409–15.
130. Gray A, Raikou M, McGuire A, Fenn P, Stevens R,
Cull C, et al. Cost effectiveness of an intensive
blood glucose control policy in patients with type 2
diabetes: economic analysis alongside randomised
controlled trial (UKPDS 41). United Kingdom
Prospective Diabetes Study Group. BMJ
2000;320:1373–8.
131. Stratton IM, Adler AI, Neil HA, Matthews DR,
Manley SE, Cull CA, et al. Association of glycaemia
with macrovascular and microvascular
complications of type 2 diabetes (UKPDS 35):
prospective observational study. BMJ
2000;321:405–12.
132. Klein R, Klein BE, Moss SE, Cruickshanks KJ.
The Wisconsin Epidemiologic Study of Diabetic
Retinopathy: XVII. The 14-year incidence and
progression of diabetic retinopathy and associated
risk factors in type 1 diabetes. Ophthalmology
1998;105:1801–15.
133. Effect of intensive blood-glucose control with
metformin on complications in overweight
patients with type 2 diabetes (UKPDS 34). UK
Prospective Diabetes Study (UKPDS) Group.
Lancet 1998;352:854–65.
134. Clark P, Gray A, Adler A, Stevens R, Raikou M,
Cull C, et al. Cost-effective analysis of intensive
blood glucose control with metformin in
overweight patients with type 2 diabetes (UKPDS
51). Diabetologia 2001;44:298–304.
135. Palmer AJ, Weiss C, Sendi PP, Neeser K, Brandt A,
Singh G, et al. The cost-effectiveness of different
management strategies for type I diabetes: a Swiss
perspective. Diabetologia 2000;43:13–26.
136. INPUT. INsulin PUmp Therapy. 2001.
137. Directory of diabetes care. Cambridge: CMA Medical
Data; 2001.
138. Netten A, Rees T, Harrison G. Unit costs of health
and social care, 2001. Canterbury: Personal Social
Services Research Unit, University of Kent at
Canterbury; 2002.
139. NHS. NHS reference costs. London: Department of
Health; 2000.
140. Nordfeldt S, Jonsson D. Short-term effects of
severe hypoglycaemia in children and adolescents
with type 1 diabetes. A cost-of-illness study. Acta
Paediatr 2001;90:137–42.
141. Leese GP, Wang J, Broomhall J, Kelly P, Marsden A,
Morrison W, et al. Incidence of severe
hypoglycaemia requiring emergency treatment in
type 1 and type 2 diabetes: a population-based
study of health service resource use. Diabet Med
2002;19 (Suppl 2):12–3.
142. Rubin RR, Peyrot M. Quality of life and diabetes.
Diabetes Metab Res Rev 1999;15:205–18.
143. The Diabetes Control and Complications Trial
Research Group. The relationship of glycemic
exposure (HbA1c) to the risk of development and
progression of retinopathy in the diabetes control
and complications trial. Diabetes 1995;44:968–83.
144. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL.
Glycosylated hemoglobin predicts the incidence
and progression of diabetic retinopathy. JAMA
1988;260:2864–71.
145. Klein R, Klein BE. Relation of glycemic control to
diabetic complications and health outcomes.
Diabetes Care 1998;21 (Suppl 3):C39–43.
146. Epidemiology of severe hypoglycemia in the
diabetes control and complications trial. The
DCCT Research Group. Am J Med 1991;90:450–9.
147. Microvascular and acute complications in IDDM
patients: the EURODIAB IDDM Complications
Study. Diabetologia 1994;37:278–85.
148. Influence of intensive diabetes treatment on
quality-of-life outcomes in the diabetes control and
complications trial. Diabetes Care 1996;19:195–203.
149. Ferguson SC, Strachan MW, Janes JM, Frier BM.
Severe hypoglycaemia in patients with type 1
diabetes and impaired awareness of
hypoglycaemia: a comparative study of insulin
lispro and regular human insulin. Diabetes Metab
Res Rev 2001;17:285–91.
150. Marrero DG, Guare JC, Vandagriff JL, Fineberg NS.
Fear of hypoglycemia in the parents of children
and adolescents with diabetes: maladaptive or
healthy response? Diabetes Educ 1997;23:281–6.
151. Cox DJ, Irvine A, Gonder-Frederick L, Nowacek
G, Butterfield J. Fear of hypoglycaemia:
quantification, validation and utilisation. Diabetes
Care 1987;10:6717–621.
152. Clarke WL, Cox DJ, Gonder-Frederick LA,
Julian D, Schlundt D, Polonsky W. Reduced
awareness of hypoglycemia in adults with IDDM. A prospective study of hypoglycemic frequency and associated symptoms. Diabetes Care 1995;
18:517–22.
153. Gold AE, MacLeod KM, Frier BM. Frequency of
severe hypoglycaemia in patients with type 1
diabetes with impaired awareness of
hypoglycaemia. Diabetes Care 1994;17:697–703.
154. Chantelau E, Schiffers T, Schutze J, Hansen B.
Effect of patient-selected intensive insulin therapy
on quality of life. Patient Educ Couns
1997;30:167–73.
155. Lewis KS, Bradley C, Knight G, Boulton AJM,
Ward JD. A measure of treatment satisfaction
designed specifically for people with insulindependent
diabetes. Diabet Med 1988;5:235–42.
156. Johansson UB, Adamson UC, Lins PE,
Wredling RA. Improved blood glucose variability,
HbA1c insuman Infusat and less insulin
requirement in IDDM patients using insulin lispro
in CSII. The Swedish Multicenter Lispro Insulin
Study. Diabetes Metab 2000;26:192–6.
157. Wu S, Sainfort F, Tomar R, Tollios JL, Fryback DG.
Development and application of a model to
estimate the impact of type 1 diabetes on healthrelated
quality of life. Diabetes Care 1998;21:725–31.
158. Brown MM, Brown GC, Sharma S, Shah G. Utility
values and diabetic retinopathy. Am J Ophthalmol
1999;128:324–30.
159. Kiberd BA, Jindal KK. Screening to prevent renal
failure in insulin dependent diabetic patients: an
economic evaluation. BMJ 1995;311:1595–9.
160. Tomar R, Lee S, Wu S, Klein R, Moss SE,
Fryback DG, et al. Disease progression and cost of
insulin dependent diabetes mellitus: development
and application of simulation model. J Soc Health
Syst 1998;5:24–37.
161. Dolan P. Modelling valuations for EuroQol health
states. Med Care 1997;35:1095–108.
162. Gerich JE. Selection of patients for intensive
insulin therapy. Arch Intern Med 1985;145:1383–4.
163. Hanas R. Selection for and initiation of continuous
subcutaneous insulin infusion. Proceedings from a
workshop. Horm Res 2002;57 (Suppl 1):101–4.
164. Marshall SM, Home PD, Taylor R, Alberti KG.
Continuous subcutaneous insulin infusion versus
injection therapy: a randomised cross-over trial
under usual diabetic clinic conditions. Diabet Med
1987;4:521–5.
165. Helve E, Koivisto VA, Lehtonen A, Pelkonen R,
Huttunen JK, Nikkila EA. A crossover comparison
of continuous insulin infusion and conventional
injection treatment of type I diabetes. Acta Med
Scand 1987;221:385–93.
166. Scottish Study Group for the Care of the Young
Diabetic. Factors influencing glycemic control in
young people with type 1 diabetes in Scotland.
Diabetes Care 2001;24:239–44.
167. Warren E, Weatherley-Jones E, Chilcott J,
Beverley C. Systematic review and economic
evaluation of a long-acting insulin analogue,
insulin glargine. Health Technol Assess 2004;8
(in press).
168. Schober E, Schoenle E, van Dyk J,
Wernike-Panten K. Comparative trial between
insulin glargine and NPH insulin in children and
adolescents with type 1 diabetes. Diabetes Care
2001;24:2005–6.
169. Armstrong DU, King AB. Basal insulin: continuous
glucose monitoring reveals less overnight
hypoglycaemia with continuous subcutaneous
insulin infusion than with glargine. Diabetes
2002;51 (Suppl 2, poster 373):92A.
170. Elbourne DR, Altman DG, Higgins JPT, Curtin F,
Worthington HV, Vail A. Meta-analyses involving
cross-over trials: methodological issues. Int J
Epidemiol 2002;31:140–9.
171. Chilcott J, Wight J, Lloyd Jones M, Tappenden P.
The clinical effectiveness and cost effectiveness of
pioglitazone in Type 2 diabetes mellitus: a rapid
and systematic review. Health Technol Assess
2001;5(19).